Tag Archives: Novartis Strengthens US Radioligand Therapy Production with Planned Texas Manufacturing Investment

Novartis Advances Cancer Treatment Manufacturing Strategy with New Radioligand Facility in Dallas Fort Worth Region

(IN BRIEF) Novartis has announced plans to establish a 46,000-square-foot radioligand therapy manufacturing facility in Denton, Texas, with operations expected to begin in 2028. The new site will expand the company’s U.S. manufacturing network and support growing demand for targeted … Read the full press release